S-3ASR filed Nov 12, 2026 at 16:02 ET
Vir Biotechnology filed an automatic shelf registration (S-3ASR) to register an unlimited amount of senior and subordinated debt securities for future issuance. The filing does not specify any immediate offering size, pricing, or use of proceeds. The company has $901.3M in cash and investments as of September 30, 2026, and recently entered a Gilead collaboration worth up to $1.74B in milestones, suggesting this shelf is opportunistic rather than a distress-driven capital raise. The filing follows a recent activist stake reduction by ARCH Venture Fund and a Q3 2026 earnings report showing a narrowed net loss.